This document outlines details of PBS-subsidised aflibercept, brolucizumab, dexamethasone intravitreal implant, faricimab and ranibizumab for patients with eye conditions.
For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Subfoveal choroidal neovascularisation (CNV) quick reference
Diabetic macular oedema (DMO) quick reference
Proliferative diabetic retinopathy (PDR) and/or DMO quick reference
Retinal vein occlusion (RVO) quick reference
Eye program assessing table for CNV
Subfoveal choroidal neovascularisation (CNV) quick reference
Table 1
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB072 form | Written Electronic S85: aflibercept brolucizumab faricimab ranibizumab | No | OPA | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| Yes |
Continuing | Streamlined S85: aflibercept faricimab ranibizumab | No | N/A | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| N/A |
Continuing | Telephone Electronic S85: brolucizumab | No | OPA | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| Yes |
Diabetic macular oedema (DMO) quick reference
Table 2
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial | Telephone Electronic S85: aflibercept dexamethasone intravitreal implant faricimab | No | OPA | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| Yes |
Continuing | Streamlined S85: aflibercept dexamethasone intravitreal implant faricimab | No | N/A | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| N/A |
Proliferative diabetic retinopathy (PDR) and/or DMO quick reference
Table 3
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial | Telephone Electronic S85: ranibizumab | No | OPA | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| Yes |
Continuing | Streamlined S85: ranibizumab | No | N/A | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| N/A |
Retinal vein occlusion (RVO) quick reference
Table 4
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB154 form | Written Electronic S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab | No | OPA | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| Yes |
Continuing | Streamlined S85: aflibercept dexamethasone intravitreal implant faricimab ranibizumab | No | N/A | Must be treated by an: - ophthalmologist
- accredited ophthalmology registrar in consultation with an ophthalmologist
| N/A |
Eye program assessing table for CNV
Table 5
Drug | Condition | Clinical criteria | Result |
Lucentis (Ranibizumab) | CNV | Not stated | Reject |
Lucentis (Ranibizumab) | CNV | Due to age-related macular degeneration (AMD), pathologic myopia (PM) or causes other than AMD/PM | Approve |
Lucentis (Ranibizumab) | Not stated | Due to AMD, PM or causes other than AMD/PM | Reject |
All | Multiple indications and/or criteria specified | Multiple listed | Reject |
Eylea (Aflibercept) | CNV | Not stated | Reject |
Eylea (Aflibercept) | Not stated | Due to AMD | Reject |
Eylea (Aflibercept) | CNV | Due to AMD or PM | Approve |
Eylea (Aflibercept 8 mg/0.07 mL) | CNV | Not stated | Reject |
Eylea (Aflibercept 8 mg/0.07 mL) | Not stated | Due to AMD | Reject |
Eylea (Aflibercept 8 mg/0.07 mL) | CNV | Due to AMD | Approve |
Beovu (Brolucizumab) | CNV | Due to AMD | Approve |
Beovu (Brolucizumab) | CNV | Not stated | Reject |
Beovu (Brolucizumab) | Not stated | Due to AMD | Reject |
Vabysmo (Faricimab) | CNV | Due to AMD | Approve |
Vabysmo (Faricimab) | CNV | Not stated | Reject |
Vabysmo (Faricimab) | Not stated | Due to AMD | Reject |
Expand all